Beste apotheek van Nederland

Table 17: Intra-urethral Treatment: Sexual Intercourse………………………………………...152
Table 18: Intra-urethral Treatment: Improvement in Erections ……………………………….154
Table 19: Intra-urethral Treatment: Patients With Adverse Events…………………………….155
Table 20: Alprostadil (Topical Cream) vs. Placebo: Sexual Encounter Profile (SEP)…………158
Table 21: Topical Treatment: Improvement in Erections ……………………………………..158
Table 22: Topical Treatment: Patients With Adverse Events
..........................................................................................…………………………………...160
Table 23: Testosterone: Improvement in Sexual Intercourse Outcomes...........................……..162
Table 24: Testosterone (T) Combined With PDE–5 inhibitors: Improvement in Sexual
Intercourse Outcomes…………………………………………………………………………..164
Table 25: Testosterone Treatment: Improvement in Erections…………………………………166
Table 26: Testosterone Treatment: Patients With Adverse Events ……………………...……171
Table 27: Miscellaneous Treatments: Efficacy and Adverse Events…………………………...175
Table 28: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)………………………..177
Table 29: Penile Fibrosis in Studies of Intracavernosal Injection (Non-randomized)………….179
Figures
Figure 1. Analytic Framework for the Diagnosis and Treatment of Erectile Dysfunction....... …18
Figure 2. Modified QUOROM Flow Chart .............................................................................. …22
Figure 3. The Mean IIEF “EF Domain” Score ......................................................................... ..182
Figure 4. The Mean IIEF–Q3 Score ......................................................................................... ..182
Figure 5. The Mean IIEF–Q4 Score ......................................................................................... ..182
Figure 6. Improved Erection (GEQ–Q1) .................................................................................. ..183
Figure 7. Any Adverse Events (All Causes)............................................................................. ..183
Figure 8. Any Treatment-related Adverse Events .................................................................... ..183
Figure 9. Headache (All Causes) .............................................................................................. ..184
Figure 10. Flushing (All Causes).............................................................................................. ..184
Figure 11. Visual Disturbances................................................................................................. ..185
Figure 12. Improved Erection (GEQ–Q1): Type I and II Diabetes Patients Combined........... ..185
Figure 13. Improved Erection (GEQ–Q1): Type II Diabetes Patients Only............................. ..186
Figure 14. The Mean IIEF–Q3 Score: Type I and II Diabetes Patients Combined.................. ..186
Figure 15. The Mean IIEF–Q4 Score: Type I and II Diabetes Patients Combined.................. ..186
Figure 16. Any Treatment-related Adverse Event: Type I and II Diabetes Patients Combined 187
Figure 17. Any Treatment-related Adverse Events:Type II Diabetes Oatients Only............... ..187
Figure 18. Successful Intercourse Attempts: Patients With Major Depressive Disorder in
Remission………………………………………………………………………………………..187
Figure 19. Improved Erection (GEQ–Q1): Patients With Major Depressive Disorder in
Remission.................................................................................................................................. ..187
Figure 20. The Mean IIEF–Q3 Score: Patients With Major Depressive Disorder in Remission.188
Figure 21. The Mean IIEF–Q4 Score: Patients With Major Depressive Disorder in Remission 188
Figure 22 The Mean IIEF–Q3 Score: Patients With Hypertension on Antihypertensive Drugs 188
Figure 23. The Mean IIEF–Q4 Score: Patients With Hypertension on Antihypertensive Drugs
………………………................................................................................................... …189
Figure 24. Improved Erection (GEQ–Q1): Patients With Hypertension on Antihypertensive
Drugs……………..................................................................................................................... ..189
ix